Malignant mast cell neoplasm Active Not Recruiting Phase 2 Trials for Alemtuzumab (DB00087)

Also known as: Malignant Mast Cell Tumors / Leukemia, Mast Cell / Mast Cell Leukemia / Mast Cell Leukemia (MCL) / Malignant-mast cell tumours / Aggressive systemic mastocytosis / Mast-Cell Sarcoma

IndicationStatusPhase
DBCOND0007107 (Malignant mast cell neoplasm)Active Not Recruiting2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00118352Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic CancerTreatment